PMID- 36682035
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230202
IS  - 2730-6011 (Electronic)
IS  - 2730-6011 (Linking)
VI  - 14
IP  - 1
DP  - 2023 Jan 22
TI  - The survival rate of laryngeal squamous cell carcinoma: impact of IL1RAP 
      rs4624606, IL1RL1 rs1041973, IL-6 rs1800795, BLK rs13277113, and TIMP3 rs9621532 
      single nucleotide polymorphisms.
PG  - 8
LID - 10.1007/s12672-023-00619-0 [doi]
LID - 8
AB  - PURPOSE: Results of laryngeal squamous cell carcinoma (LSCC) treatment and the 
      5 year survival rate of these patients remain poor. To purify therapeutic 
      targets, investigation of new specific and prognostic blood-based markers for 
      LSCC development is essential. METHODS: In the present study, we evaluated five 
      single nucleotide polymorphisms (SNPs): IL1RAP rs4624606, IL1RL1 rs1041973, IL-6 
      rs1800795, BLK rs13277113, and TIMP3 rs9621532, and determined their associations 
      with the patients' 5 year survival rate. Also, we performed a detailed 
      statistical analysis of different LSCC patients' characteristics impact on their 
      survival rate. RESULTS: Three hundred fifty-three LSCC patients and 538 control 
      subjects were included in this study. The multivariable Cox regression analysis 
      revealed a significant association between patients' survival rate and 
      distribution of IL1RAP rs4624606 variants: patients carrying AT genotype at 
      IL1RAP rs4624606 had a lower risk of death (p = 0.044). Also, it was revealed 
      that tumor size (T) (p = 0.000), tumor differentiation grade (G) (p = 0.015), and 
      IL1RAP rs4624606 genotype (p = 0.044) were effective variables in multivariable 
      Cox regression analysis prognosing survival of LSCC patients. The specific-LSCC 
      5 year survival rate was 77%. CONCLUSIONS: In summary, our findings indicate that 
      the genotypic distribution of IL1RAP rs4624606 influences the 5 year survival 
      rate of LSCC patients. The results of the present study facilitate a more 
      complete understanding of LSCC at the biological level, thus providing the base 
      for the identification of new specific and prognostic blood-based markers for 
      LSCC development.
CI  - (c) 2023. The Author(s).
FAU - Pasvenskaite, Agne
AU  - Pasvenskaite A
AUID- ORCID: 0000-0003-0660-2953
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences 
      (LUHS), A. Mickeviciaus 9, LT 44307, Kaunas, Lithuania. 
      pasvenskaite.agne@gmail.com.
FAU - Liutkeviciene, Rasa
AU  - Liutkeviciene R
AUID- ORCID: 0000-0001-5395-923X
AD  - Neuroscience Institute, Lithuanian University of Health Sciences (LUHS), Kaunas, 
      Lithuania.
FAU - Gedvilaite, Greta
AU  - Gedvilaite G
AUID- ORCID: 0000-0001-7469-8825
AD  - Neuroscience Institute, Lithuanian University of Health Sciences (LUHS), Kaunas, 
      Lithuania.
FAU - Vilkeviciute, Alvita
AU  - Vilkeviciute A
AUID- ORCID: 0000-0002-0427-5568
AD  - Neuroscience Institute, Lithuanian University of Health Sciences (LUHS), Kaunas, 
      Lithuania.
FAU - Liutkevicius, Vykintas
AU  - Liutkevicius V
AUID- ORCID: 0000-0002-7349-4844
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences 
      (LUHS), A. Mickeviciaus 9, LT 44307, Kaunas, Lithuania.
FAU - Uloza, Virgilijus
AU  - Uloza V
AUID- ORCID: 0000-0003-4331-319X
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences 
      (LUHS), A. Mickeviciaus 9, LT 44307, Kaunas, Lithuania.
LA  - eng
PT  - Journal Article
DEP - 20230122
PL  - United States
TA  - Discov Oncol
JT  - Discover oncology
JID - 101775142
PMC - PMC9867797
OTO - NOTNLM
OT  - BLK rs13277113
OT  - IL-6 rs1800795
OT  - IL1RAP rs4624606
OT  - IL1RL1 rs1041973
OT  - Laryngeal squamous cell carcinoma
OT  - TIMP3 rs9621532
COIS- The authors declare no competing interests.
EDAT- 2023/01/23 06:00
MHDA- 2023/01/23 06:01
PMCR- 2023/01/22
CRDT- 2023/01/22 14:06
PHST- 2022/11/18 00:00 [received]
PHST- 2023/01/16 00:00 [accepted]
PHST- 2023/01/22 14:06 [entrez]
PHST- 2023/01/23 06:00 [pubmed]
PHST- 2023/01/23 06:01 [medline]
PHST- 2023/01/22 00:00 [pmc-release]
AID - 10.1007/s12672-023-00619-0 [pii]
AID - 619 [pii]
AID - 10.1007/s12672-023-00619-0 [doi]
PST - epublish
SO  - Discov Oncol. 2023 Jan 22;14(1):8. doi: 10.1007/s12672-023-00619-0.